CLEW

Company Overview

Snapshot

Founded in December 2014 by Gal Salomon and Avigdor Faians, CLEW operates with 11–50 employees. The company has raised $20.5 million across six funding rounds from five investors.

Business overview

CLEW leverages artificial intelligence and data science to develop patient-level physiological predictive models. Originally proven in intensive care units (ICU), these models are now expanding to all care settings, assisting healthcare providers in forecasting patient states. The company's technology, deployable from the bedside to centralized command-and-control facilities, aims to enhance clinical decision-making, improve patient outcomes and safety, streamline care, and reduce costs. CLEW operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Medical Decision Support, serving healthcare providers in markets such as the United States, Europe, and Israel.

Strategic signal

In June 2024, CLEW Medical partnered with AvaSure to enhance high-acuity care through AI-driven virtual surveillance. This collaboration signals a strategic move to integrate CLEW's predictive analytics with virtual care platforms, expanding its reach and impact within critical care settings and validating the company's technology as a key component for advanced remote patient monitoring solutions.

Company Intelligence Q&A

What was a significant product launch for CLEW in 2025?

In March 2025, CLEW launched its Sepsis Virtual Unit (SVU), designed to enhance SEP-1 compliance and improve patient outcomes through AI-driven clinical surveillance.

What strategic partnership did CLEW form in 2024?

In June 2024, CLEW Medical teamed up with AvaSure to boost high-acuity care with AI-driven virtual surveillance, integrating CLEW's predictive analytics into AvaSure's platform.

What recent expansion did CLEW announce regarding its platform?

In April 2024, CLEW announced the expansion of its intelligent clinical surveillance platform to cover all inpatient settings, moving beyond its initial focus on ICUs.

What was a key finding from a study involving CLEW's AI models in 2024?

In April 2024, a new study found that CLEW's AI-driven prediction models accurately predict critical care patient deterioration and significantly reduce false alarms for clinicians.

When did CLEW receive FDA clearance for its AI-based predictive analytics technology?

In February 2021, CLEW Medical received FDA clearance for its AI-based predictive analytics technology, supporting patient assessment in adult intensive care units.